A federal jury has found that Teva must pay GlaxoSmithKline $235 million in a carve-out patent case over heart drug Coreg.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.

Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.

Seqirus said it has achieved an industry first by producing a cell-based influenza vaccine on a commercial scale using a virus grown in cells.

It’s a two-fer for McCann Health. The agency won Cannes Lions Health network advertising agency of the year for the second year in a row.

Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.

A new Supreme Court decision could throw into question $300 million in talc verdicts against Johnson & Johnson.

Mylan, which already has a low tax rate by being based in the Netherlands, has cut it into the single digits by investing in refined coal plants.

After scoring impressive numbers with its science-focused TV ad, Pfizer is preparing to launch another next month starring one of its own scientists.